Biolase (BIOL – Research Report) received a Hold rating and price target from Maxim Group analyst Anthony Vendetti yesterday. The company’s shares closed yesterday at $0.15.
Vendetti covers the Healthcare sector, focusing on stocks such as Biolase, Nuwellis, and Lucid Diagnostics. According to TipRanks, Vendetti has an average return of -6.2% and a 33.00% success rate on recommended stocks.
Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.20.
The company has a one-year high of $21.56 and a one-year low of $0.13. Currently, Biolase has an average volume of 5.56M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biolase (BIOL) Company Description:
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
